# US 6,730,489 B1 · Antibodies to truncated VEGF-D and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,489 B1
- Document ID: US6730489B1
- Status: Granted
- Kind: B1
- Application number: 10/100,037
- Filed: 2002-03-19
- Granted: 2004-05-04
- Earliest claimed: 1998-12-21
- Assignees: Ludwig Institute for Cancer Research
- Inventors: Marc G. Achen; Steven Alan Stacker
- Web page: https://patentgrep.com/patent/US6730489B1

## CPC

- C07K 16/24: against cytokines, lymphokines or interferons
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/50: characterized by immunoglobulin fragments
- Y10S 435/81: Packaged device or kit
- Y10S 530/809: Fused cells, e.g. hybridoma
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the binding of VEGF-D to VEGFR-3 but does not interfere with the activity of VEGF mediated by VEGFR-2 or bind to VEGF-C. The invention provides pharmaceutical and diagnostic compositions and methods utilizing these antibodies.

## Claims

### Claim 1

A method of detecting VEGF-D in biological sample, comprising the step of contacting the sample with an antibody or an antibody labeled with a detectable label which specifically binds to a polypeptide comprising an amino acid sequence of SEQ ID NO:1, wherein said antibody is selected from the group consisting of a monoclonal antibody of 2F8 (ATCC No. PTA-3653), 4A5 (ATCC No. HB-12698), 4E10 (ATCC No. PTA-3652, and 5F12 (ATCC No. PTA-3651), or a F(ab′)2, F(ab′), or F(ab) fragment thereof, or a chimeric antibody thereof or a humanized antibody thereof, and detecting the occurrence of binding of said antibody to VEGF-D.

### Claim 2

A method of detecting VEGF-D in biological sample, comprising the step of contacting the sample with an antibody or an antibody labeled with a detectable label which interferes with an activity of VEGF-D mediated by a VEGF receptor-2 or VEGF receptor-3, wherein said antibody is selected from the group consisting of a monoclonal antibody of 2F8 (ATCC No. PTA-3653), 4A5 (ATCC No. HB-12698), 4E10 (ATCC No. PTA-3652, and 5F12 (ATCC No. PTA-3651), or a F(ab′)2, F(ab′), or F(ab) fragment thereof, or a chimeric antibody thereof or a humanized antibody thereof, and detecting the occurrence of binding of said antibody to VEGF-D.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said antibody or said antibody labeled with a detectable label is a monoclonal antibody or a F(ab′)2, F(ab′), or F(ab) fragment thereof, or a chimeric antibody thereof.

### Claim 4 (depends on 3)

The method according to claim 3, wherein said antibody is labeled with a detectable label.

### Claim 5 (depends on 4)

The method according to claim 4, wherein said detectable label is a radioactive isotope.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said antibody is a humanized antibody.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said antibody is selected from the group consisting of 2F8 (ATCC No. PTA-3653), 4A5 (ATCC No. HB-12698), 4E10 (ATCC No. PTA-3652), and 5F12 (ATCC No. PTA-3651), or a F(ab′)2, F(ab′), or F(ab) fragment thereof.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said antibody is Mab 4A5 (ATCC No. HB-12698) or a F(ab′)2, F(ab′), or F(ab) fragment thereof.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said antibody interferes with an activity of VEGF-D mediated by a VEGF receptor-2, and is a monoclonal antibody, or a F(ab′)2, F(ab′), or F(ab) fragment or a chimeric antibody thereof.

### Claim 10 (depends on 1)

The method according to claim 1, wherein said antibody interferes with the binding of VEGF-D to a VEGF receptor-3.

### Claim 11 (depends on 1)

The method according to claim 1, wherein said antibody interferes with the binding of VEGF-D to a VEGF receptor-3, and is a monoclonal antibody, or a F(ab′)2, F(ab′), or F(ab) fragment thereof or a chimeric antibody thereof.

### Claim 12 (depends on 2)

The method according to claim 2, wherein said antibody specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:1.

### Claim 13 (depends on 2)

The method according to claim 2, wherein said antibody is a monoclonal antibody, or a F(ab′)2, F(ab′), or F(ab) fragment or a chimeric antibody thereof.

### Claim 14 (depends on 2)

The method according to claim 2, wherein said antibody is labeled with a detectable label.

### Claim 15 (depends on 14)

The method according to claim 14, wherein said detectable label is a radioactive isotope.

### Claim 16 (depends on 2)

The method according to claim 2, wherein said antibody is a humanized antibody.

### Claim 17 (depends on 2)

The method according to claim 2, wherein said antibody is selected from the group consisting of 2F8 (ATCC No. PTA-3653), 4A5 (ATCC No. HB-12698), 4E10 (ATCC No. PTA-3652), and 5F12 (ATCC No. PTA-3651), or a F(ab′)2, F(ab′), or F(ab) fragment thereof.

### Claim 18 (depends on 2)

The method according to claim 2, wherein said antibody is Mab 4A5 (ATCC No. HB-12698) or a F(ab′)2, F(ab′), or F(ab) fragment thereof.

### Claim 19 (depends on 2)

The method according to claim 2, wherein said antibody interferes with the binding of VEGF-D to a VEGF receptor-3.

### Claim 20 (depends on 2)

The method according to claim 2, wherein said antibody interferes with the binding of VEGF-D mediated by a VEGF receptor-3, and is a monoclonal antibody, or a F(ab′)2, F(ab′), or F(ab) fragment or a chimeric antibody thereof.
